J&J's Megadyne division pulls pediatric electrosurgery pad from market following patient burn recall
One of Johnson & Johnson’s medical device subsidiaries is pulling one of its pediatric electrosurgery devices from the market ...
About 100 days after implanting its first human participant with its brain-computer interface chip, Neuralink reported that ...
The FDA needs a few more weeks to decide the fate of Moderna's RSV vaccine, the company announced. A decision is now slated ...
Sanofi's CSO has left the company amid a global R&D restructuring. Pfizer tags longtime Citi analyst for C-suite-level ...
It appears that Sanofi’s loss is Shionogi’s gain. Five months after the Federal Trade Commission scuttled Sanofi’s attempt to ...
MacroGenics’ safety woes have followed into phase 2. Having dialed down the dose in response to early-phase data, the biotech ...
The FDA is alerting users and providers to Tandem Diabetes Care’s recall of its insulin pump-controlling iPhone app after a ...
The need to stretch strained bank balances has hit pipelines once again. | The need to stretch strained bank balances has hit ...
Following 12 company recalls and nearly 3,000 reported issues related to its cardiovascular life support systems since ...
Innovent has scored another phase 3 win for mazdutide as the drug showed its superiority to Eli Lilly's diabetes and heart ...
In its ongoing mission to find the next Wegovy, Novo Nordisk has penned another partnership to seek out next-gen obesity ...
Takeda has made some cuts to its clinical-phase pipeline, hacking off midphase programs and early-stage prospects as part of a push to focus on its most promising candidates. | Takeda has taken an ax ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results